Hong Kong’s Regencell Bioscience triples in latest surge for a speculative stock

Regencell Bioscience HoldingsA bioscience company based in Hong Kong at the start of Hong Kong without income, is the last speculative actions abroad to attract an unusual increase in commercial demand.

The shares of Regencell, which indicates that it develops traditional treatments of Chinese grass to treat hyperactivity disorder and the autism of the deficit in childhood attention, more than tripled on Monday – arrow of more than 280% by the fence after a Split of 38 for 1 Declared on June 2 entered into force. At the end of Monday, Regencell, founded in 2014 and was negotiated on the Nasdaq under the “RGC” Ticker since 2021, had a total market capitalization of 29.7 billion dollars, according to S&P Capital IQ.

The stock continued to jump on Tuesday, winning more than 25%. The performance of the year to date of the company is also prohibited, having increased by more than 58,000% in 2025. Its current market value of $ 36 billion Tops Lululemon, Ebay and Kraft Heinz. The shares have been negotiated against money at some point in the past year.

Regencell is the latest example of a speculative international actions attracting attention during summer trading. In August 2022, for example, Digital AMTDA Fintech company based in Hong Kong, climbed to 126%briefly giving it a market value greater than Coca-Cola And America Bank.

Earlier this month, Regencell explained the split of shares as designed only “to improve liquidity on the company’s ordinary equity market and make stock more accessible to investors”. Action divisions do not change anything fundamentally on a business.

The overvoltage of Regencell also took place in the middle of an increased accent on alternative drugs after Robert F. Kennedy Jr. was sworn as secretary of the United States Department of Health and Social Services in February. Kennedy, skeptical of the vaccine, has taken measures to Discourage routine immunizations In the United States, last week Remove all members of a panel This advises the centers for disease control and prevention on vaccines.

The Regencell stock often makes huge oscillations of a day. For example, shares jumped approximately 30% on March 21, before dropping by 30% on the following negotiation day.

Dark treatments, zero income

Despite the wild peak in the stock, little is known about the efficiency and marketing of Regencell treatments for ADHD and autistic spectrum disorders.

Regencell’s business centers on a traditional formula of traditional Chinese medicine (TCM) have developed in partnership with TCM Sik-Kee practitioner using his “Sik-Kee at TCM Brain Theory.“Sik-Kee is the Father of the Director General of Regencell Yat-Gai au, said the company in a press release in 2022.

The CEO controls 86.24% of the total number of shares in circulation, according to FactSet data.

Three liquid, to be taken orally TCM formulas To claim to attack light, moderate and severe conditions and contain only natural ingredients such as “detoxification herbs”, blood circulation herbs and digestion herbs.

“These TCM formulas constitute the basis of our TCM products candidates, which we intend to develop and market for the treatment of ADHD and TSA,” said the Regencell website.

In his Last annual report tabled last OctoberRegencell said that he had generated any turnover, nor deposited for any regulatory approval of his TCM formulas. For the exercises completed in June 2024 and 2023, Regencell underwent total net losses of $ 4.36 million and $ 6.06 million, respectively, according to a dry file.

“We have not generated income from TCM formulas of candidates or applied for regulatory approvals, no distribution or experienced capacity or patents or patent applications and may never be profitable,” read the file.

Regencell did not respond to a request for CNBC comments.

Regencell’s Latest patient case studyDated November 15, 2023, said 28 patients had received treatment over a three -month period in a second trial of efficiency and showed an improvement in symptoms of ADHD and TSA, according to the company’s web page.

In a previous case, Regencell said in 2021 press release Whether he treated a dozen patients with suspected or confirmed COVI-19 cases, using a modified version of the modified cold formula from AU. What has been described as an improvement in the Covid conditions led Regencell to form a joint venture with Honor Epic Enterprises Limited in September 2021 to carry out other tests and market the Cèfore Treatment of the Society in countries belonging to the Association of Nations of Southeast Asia, according to the press release.

Online buzz

The stock has attracted little chatting on social networks in recent years. These comments which were made suggest both the enthusiasm of retail trafficking – and skepticism.

A user on the Reddit page “R / Shortesqueeze” wrote Monday that Regencell “exchange like a play of the same. Bought a little to see what is going on and it dropped 50% just after LOL.” Another user said in a message three months ago: “I am the RGC scalp every day for a little profit.” The stock jumped 1,360% in May only.

On LinkedIn in May, an investor said he “I can’t stop laughing“After reading the description of the company. Another article from a user of the pharmaceutical industryAccording to his profile, last week, Regencell had become the “stock to watch” after its tip in May on “no official news or catalysts”. Another LinkedIn user commented last month on Regencell, saying: “Based on China, at low volume and no official news, bizarro”.

On X, a user wrote in an article on Monday: “For #COMPTEBULSH_COMPanyoftheear I name Regencell. “”

– CNBC Scott Schnipper contributed the reports.